People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. | — | Biotechnology | Series B | $105.3M | $392.4M | 2020 |
| Angion Biomedica Corp. | — | Biotechnology | Series B | $52.0M | $48.3M | 2023 |
Christopher Haqq at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Haqq on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Ruffolo | 2 | 8 |
| Robert Connelly | 2 | 4 |
| Carol Ashe | 2 | 2 |
| Yekaterina Chudnovsky | 2 | 2 |
| Julian Adams | 2 | 2 |
| Isaac Blech | 1 | 14 |
| Daniel Geffken | 1 | 6 |
| Jay Venkatesan | 1 | 5 |
| Daniel Behr | 1 | 4 |
| Ben Bronstein | 1 | 4 |
| Jay R. Venkatesan | 1 | 3 |
| William Koster | 1 | 3 |
| Alan Shaw | 1 | 2 |
| Allen Nissenson | 1 | 2 |
| Isaac Kohlberg | 1 | 2 |
| Satish Jindal | 1 | 2 |
| Daphne Karydas | 1 | 2 |
| Ofer Gonen | 1 | 2 |
| Frank Haluska | 1 | 1 |
| Steve Deitcher | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.